首页> 美国卫生研究院文献>Journal of Blood Medicine >Comparative safety of intravenous Ferumoxytol versus Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia: rationale and study design of a randomized double-blind study with a focus on acute hypersensitivity reactions
【2h】

Comparative safety of intravenous Ferumoxytol versus Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia: rationale and study design of a randomized double-blind study with a focus on acute hypersensitivity reactions

机译:静脉内阿魏酸与铁合羧甲基麦芽糖治疗缺铁性贫血的比较安全性:一项针对急性超敏反应的随机双盲研究的原理和研究设计

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundIntravenous (IV) iron is often used to treat iron deficiency anemia in patients who are unable to tolerate or are inadequately managed with oral iron. However, IV iron treatment has been associated with acute hypersensitivity reactions. The comparative risk of adverse events (AEs) with IV iron preparations has been assessed by a few randomized controlled trials, which are most often limited by small patient numbers, which lack statistical power to identify differences in low-frequency AE such as hypersensitivity reactions.
机译:背景技术静脉(IV)铁常用于治疗无法耐受或口服铁治疗不足的患者的铁缺乏性贫血。但是,静脉铁剂治疗已引起急性超敏反应。静脉输注铁制剂引起的不良事件(AE)的相对危险性已通过一些随机对照试验进行了评估,这些试验通常受到患者人数的限制,这些患者缺乏统计能力来识别低频AE的差异,例如超敏反应。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号